ZBIO
Zenas BioPharma, Inc.
28.20$
+4.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -18.6% | -28.1% | +307.6% | +101.8% | -8.3% | -9.8% | -12.2% | +9.9% | +19.1% | +94.9% | -6.2% | |
| – | -22.0% | -33.6% | +375.0% | +108.8% | -9.6% | -10.7% | -12.3% | +6.5% | +18.4% | +107.9% | -10.5% | |
| – | -21.4% | -34.7% | +395.0% | +95.7% | -11.2% | -38.5% | -77.6% | +162.6% | -4.3% | +352.1% | -60.7% | |
| – | -21.4% | -34.7% | +395.0% | +110.3% | -9.3% | -10.9% | -12.5% | +6.4% | +18.0% | +109.0% | -10.3% | |
| – | – | – | – | – | – | – | – | – | – | – | -27.3% | |
| – | +2.8% | +2.6% | -87.0% | +12.5% | +30.7% | -14.0% | +8.1% | +134.9% | +12.7% | +191.1% | +10.4% | |
| – | +49.5% | +30.4% | +28.9% | +12.5% | +30.2% | -14.2% | +8.4% | -1.5% | +19.5% | -2.4% | +7.6% | |
| – | -4.6% | -7.2% | -4.3% | -22.3% | +104.4% | +15.7% | -12.7% | -22.1% | +80.4% | -7.0% | -20.6% | |
| – | +137.1% | +63.6% | -5.3% | +80.4% | +13.6% | +16.8% | -60.4% | -18.7% | +10.4% | +25.8% | -15.1% | |
| – | +1.5% | +3.4% | – | – | – | – | – | – | – | – | +11.8% | |
| – | – | – | – | +123.5% | -13.1% | -9.0% | -15.7% | -18.0% | +23.3% | +38.7% | -26.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -8.3% | +0.0% | +0.0% | +9.0% | +0.0% | +0.0% | +0.2% | +0.7% | +10.3% | +19.6% | +13.5% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.